#Israel #share repurchase #Financial Strategy #Yokneam #InMode

InMode Announces Share Repurchase Program

InMode Ltd., a prominent player in the innovative medical technologies sector, has made headlines with the announcement of a new share repurchase program. This initiative is poised to have a significant impact on the company’s market perception and value.

Overview of the Share Repurchase Program

On March 13, 2026, InMode's Board of Directors authorized the repurchase of approximately 10% of the company’s total shares outstanding, which translates to about 6.38 million ordinary shares. This bold move comes on the heels of a robust buyback in the previous year, where InMode acquired roughly $127.4 million worth of its shares. Despite challenges in the macroeconomic landscape, InMode's consistent cash flow generation has allowed the company to pursue this strategy as a prudent use of capital at its current valuation.

The company’s management expressed a clear focus on navigating the complexities of the ongoing regional conflict while also maintaining a disciplined approach to capital allocation. The decision to repurchase shares reflects a strategic commitment to enhancing shareholder value and confidence amid fluctuating market conditions.

Funding the Repurchase

The share repurchase program is expected to be funded through available cash reserves. Repurchases will be executed in the open market or through other allowed means, taking into account prevailing market conditions and legal requirements. Importantly, this program may be subject to modifications, suspension, or discontinuation at the company's discretion, based on strategic evaluations.

InMode's Commitment to Innovation

Known for its innovative medical technologies, InMode specializes in developing, manufacturing, and marketing devices that leverage groundbreaking radio frequency (RF) technology. This technology is crucial for emerging surgical procedures as well as enhancing existing treatment methods across several medical disciplines, including plastic surgery, gynecology, dermatology, otolaryngology, and ophthalmology.

With a focus on harnessing minimally invasive RF technologies, InMode presents a highly comprehensive product line aimed at improving patient outcomes while also catering to expansive market demands.

Looking Ahead

As InMode continues to evaluate further share repurchase opportunities and other capital allocation strategies, the market is watching closely to see how these moves will resonate with investors and affect the company's positioning going forward.

The forward-looking statements made by InMode underscore the inherent uncertainties and risks associated with predicting future company performance. Shareholders are encouraged to consider these factors as the company progresses with its strategic initiatives.

In summary, InMode's decision to launch this share repurchase program not only reflects its confidence in long-term financial health but also serves to fortify its commitment to stakeholders as it navigates through both challenges and opportunities in the evolving medical technology landscape.

For more information about InMode, interested parties can visit www.inmodemd.com.